Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Atrial Coronary Circulation in STEMI Patients With Newly Diagnosed Atrial Fibrillation (ACC-AF-STEMI)

14. November 2026 aktualisiert von: Prof. Dmitry Duplyakov FESC, Samara Regional Cardiology Dispensary

Atrial Coronary Circulation in STEMI Patients With Newly Diagnosed Atrial Fibrillation (ACC-AF-STEMI)

This multicenter, prospective, observational, comparative cohort study will investigate the association between atrial coronary artery involvement and newly diagnosed atrial fibrillation (AF) in patients with ST-segment elevation myocardial infarction (STEMI).

Patients with acute STEMI undergoing coronary angiography will be assigned to two observational cohorts according to the development of AF during the first 24 hours of hospitalization: patients with a first-ever episode of AF and patients without AF, with the latter group matched by age and sex. Coronary angiograms will be assessed for thrombosis or stenosis of the arteries supplying the atria and for their relationship to the infarct-related artery.

The primary endpoint is the incidence of atrial coronary artery involvement in patients with newly diagnosed AF during acute STEMI. Secondary endpoints include all-cause and cardiovascular mortality, acute heart failure, thromboembolic complications, major bleeding, duration of hospitalization and intensive care stay, AF recurrence, cardioversion, and prescription of direct oral anticoagulants during hospitalization.

The study plans to enroll 400 participants, with 200 patients in each cohort. The study is non-interventional, and all diagnostic and therapeutic procedures will be performed according to standard clinical care. The follow-up will include the index hospitalization and a 30-day telephone assessment.

Studienübersicht

Status

Noch keine Rekrutierung

Detaillierte Beschreibung

Atrial fibrillation (AF) is a common complication of acute ST-segment elevation myocardial infarction (STEMI) and is associated with adverse clinical outcomes, including acute heart failure, thromboembolic complications, prolonged hospitalization, and increased mortality. Despite advances in reperfusion therapy and contemporary STEMI management, the mechanisms underlying the development of newly diagnosed AF during acute STEMI remain incompletely understood. In particular, the potential role of the coronary arteries supplying the atrial myocardium has not been sufficiently characterized.

The ACC-AF-STEMI study is a multicenter, prospective, observational, comparative cohort study designed to investigate the association between atrial coronary artery involvement and the development of de novo AF during acute STEMI. The scientific hypothesis is that thrombosis or atherosclerotic lesions of the arteries supplying the atria, particularly when these vessels are related to the infarct-related artery, may contribute to the development of AF during the acute phase of STEMI.

Patients with a verified diagnosis of STEMI who undergo coronary angiography will be prospectively enrolled. Participants will be divided into two observational cohorts according to the development of AF during the first 24 hours of hospitalization. The main cohort will include patients with a first-ever episode of AF occurring during acute STEMI. The comparison cohort will include patients with STEMI who do not develop AF during hospitalization and will be matched by age and sex.

The key study procedure is systematic assessment of coronary angiograms. In addition to evaluation of the infarct-related artery and multivessel coronary disease, the angiographic analysis will assess thrombosis or stenosis of the arteries supplying the atria, including the right ostial/conus-related atrial branches (ROCS), atrioventricular nodal artery (AVNA), right inferior atrial artery (RIAA), and left inferior atrial artery (LIAA), as specified in the protocol. Their origin and relationship to the infarct-related artery, as well as TIMI flow before and after percutaneous coronary intervention (PCI), will be documented. Angiographic assessment will be performed by a specialized angiography committee blinded to the patient's AF status in order to minimize assessment bias.

AF will be identified using continuous electrocardiogram (ECG) monitoring during the initial intensive care unit (ICU) period, daily 12-lead ECGs, and recording of symptomatic episodes. Echocardiographic assessment will include left atrial volume index, mitral regurgitation, left ventricular ejection fraction according to the Simpson method, pulmonary artery systolic pressure, and E/E'. Clinical, laboratory, ECG, echocardiographic, angiographic, procedural, and treatment data will be prospectively recorded in an electronic case report form.

The primary endpoint is the incidence of atrial coronary artery involvement in patients with newly diagnosed AF during acute STEMI. Secondary endpoints include all-cause mortality, cardiovascular mortality, development of acute heart failure (Killip class ≥ II), thromboembolic complications including stroke and pulmonary embolism, and major bleeding defined as Bleeding Academic Research Consortium (BARC) grade ≥3. Additional outcomes include duration of hospitalization and ICU stay, type and number of cardioversions, recurrence of AF during hospitalization, failure to restore sinus rhythm, and prescription of direct oral anticoagulants during hospitalization.

The planned target sample size is 400 patients, with 200 participants in each cohort. The protocol's sample-size calculation was based on an expected difference in atrial coronary artery involvement between patients with STEMI and newly diagnosed AF and those without AF. The larger target sample is intended to support multivariable analysis and account for potential technical limitations in angiographic assessment and the relatively low prevalence of AF among patients with STEMI.

Patient recruitment is planned over 12 months. Each participant will be followed during the index hospitalization, with assessment of acute clinical outcomes, and will additionally undergo a 30-day telephone follow-up. The study is planned as a multicenter and multinational investigation, with the Samara Regional Clinical Cardiology Dispensary named after V.P. Polyakov serving as the initiating center and additional PCI-capable hospitals participating through the STEMI network.

The study is non-interventional. Coronary angiography, PCI, pharmacological treatment, cardioversion, anticoagulant therapy, and other diagnostic or therapeutic procedures will be performed solely according to clinical indications and applicable standards of care. Participation in the study does not determine or modify the treatment received by patients.

Safety information, including serious adverse events occurring from coronary angiography through hospital discharge and during the 30-day follow-up period, will be recorded. Events of particular interest include procedure-related death, stroke, major bleeding, acute kidney injury, coronary artery perforation or aortic dissection, emergency сoronary artery bypass grafting (CABG), thromboembolic complications, severe bradycardia or sinus arrest requiring temporary pacing, and cardiac tamponade.

The study is intended to improve understanding of the relationship between atrial coronary artery involvement and newly diagnosed AF during acute STEMI and to characterize the clinical and angiographic features associated with this complication.

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

1200

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

Studienorte

      • Samara, Russland, 443070
        • Samara Regional Cardiology Dispansery
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 75 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

Adults with acute ST-elevation myocardial infarction (STEMI) admitted within 24 hours of symptom onset and undergoing coronary angiography with or without percutaneous coronary intervention (PCI). The study includes patients with no previous history of atrial fibrillation who either develop first-ever atrial fibrillation within the first 24 hours of hospitalization or remain free of atrial fibrillation during hospitalization. The comparison cohort is matched by age and sex.

Beschreibung

Inclusion Criteria:

- Main cohort - STEMI patients with newly diagnosed atrial fibrillation: Age 18-75 years. ST-elevation myocardial infarction (STEMI) with symptom onset within 24 hours before enrollment.

No history of atrial fibrillation before the index STEMI. First-ever episode of atrial fibrillation documented within the first 24 hours of hospitalization.

Coronary angiography with or without percutaneous coronary intervention (PCI). Written informed consent.

- Control cohort - STEMI patients without atrial fibrillation:

Age ≥18 years. STEMI with symptom onset within 24 hours before enrollment. No history of atrial fibrillation before the index STEMI. No first-ever episode of atrial fibrillation during hospitalization. Coronary angiography with or without PCI. Written informed consent.

Exclusion Criteria:

  1. Known history of AF prior to STEMI.
  2. Time from onset of STEMI symptoms > 24 hours.
  3. Chronic Obstructive Pulmonary Disease stage ≥2.
  4. History of Myocardial Infarction.
  5. History of previous PCI or CABG.
  6. History of Valve Surgery.
  7. Mitral or Tricuspid Valve insufficiency grade ≥ 2.
  8. Hemodynamically significant Mitral Stenosis (<1.5 cm2).
  9. Permanent pacemaker.
  10. Malignancy in the active treatment phase or terminal cancer.
  11. Severe comorbidities (e.g., end-stage CKD, cirrhosis) with a life expectancy of less than 1 year.
  12. Known thyrotoxicosis.
  13. Non-invasive treatment strategy.
  14. Patient's refusal to participate in the study.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Beobachtungsmodelle: COHORT
  • Zeitperspektiven: PROSPECTIVE

Kohorten und Interventionen

Gruppe / Kohorte
Intervention / Behandlung
STEMI With Newly Diagnosed Atrial Fibrillation

Patients with STEMI who develop a first-ever episode of atrial fibrillation during the first 24 hours of hospitalization. Patients have no history of atrial fibrillation before STEMI and undergo coronary angiography with or without subsequent PCI.

Presence of thrombosis and/or stenosis of atrial coronary artery branches (ROCS, AVNA, RIAA, and LIAA), including their relationship to the infarct-related artery and TIMI flow, assessed by coronary angiography. This exposure is not assigned by the study investigators and is observed during standard-of-care coronary angiography.

STEMI Without Atrial Fibrillation

Patients with STEMI who do not develop atrial fibrillation during hospitalization. Patients have no history of atrial fibrillation before STEMI and undergo coronary angiography with or without subsequent PCI. The comparison cohort is matched by age and sex.

Presence of thrombosis and/or stenosis of atrial coronary artery branches (ROCS, AVNA, RIAA, and LIAA), including their relationship to the infarct-related artery and TIMI flow, assessed by coronary angiography. This exposure is not assigned by the study investigators and is observed during standard-of-care coronary angiography.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Incidence of atrial coronary artery involvement in patients with newly diagnosed atrial fibrillation during acute STEMI
Zeitfenster: At the time of coronary angiography

Atrial coronary artery involvement is defined as the presence of thrombosis and/or stenosis of atrial coronary artery branches (ROCS, AVNA, RIAA, and LIAA), including assessment of their relationship to the infarct-related artery and TIMI flow, as determined by coronary angiography.

At the time of coronary angiography

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
All-cause mortality
Zeitfenster: On discharge from the hospital, an average of 14 days

Death from any cause during hospitalization

On discharge from the hospital, an average of 14 days
Cardiovascular mortality
Zeitfenster: On discharge from the hospital, an average of 14 days

Death from cardiovascular disease during hospitalization

On discharge from the hospital, an average of 14 days
Acute heart failure, Killip class II or higher
Zeitfenster: On discharge from the hospital, an average of 14 days

Development of acute heart failure (Killip stage ≥ II)

On discharge from the hospital, an average of 14 days
Thromboembolic complications
Zeitfenster: On discharge from the hospital, an average of 14 days

Development of thromboembolic complications (stroke, pulmonary embolism)

On discharge from the hospital, an average of 14 days
Major bleeding, BARC grade 3 or higher
Zeitfenster: On discharge from the hospital, an average of 14 days

Bleeding (BARC score ≥ 3)

On discharge from the hospital, an average of 14 days

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

11. November 2026

Primärer Abschluss (Geschätzt)

1. November 2027

Studienabschluss (Geschätzt)

1. März 2028

Studienanmeldedaten

Zuerst eingereicht

21. September 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

14. November 2026

Zuerst gepostet (Tatsächlich)

17. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

17. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

14. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

UNENTSCHIEDEN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren